According to ANI Pharmaceuticals's latest financial reports and stock price the company's current Operating Margin is -9.64%. At the end of 2021 the company had an Operating Margin of -25.94%.
Year | Operating Margin | Change |
---|---|---|
2021 | -25.94% | 108.27% |
2020 | -12.45% | -914.76% |
2019 | 1.53% | -84.63% |
2018 | 9.95% | 7.59% |
2017 | 9.24% | 37.03% |
2016 | 6.75% | -76.31% |
2015 | 28.48% | -17.76% |
2014 | 34.62% | 8166.32% |
2013 | 0.42% | -100.03% |
2012 | -1,210.03% | -89.66% |
2011 | -11,703.01% | 564% |
2010 | -1,762.50% | -42.3% |
2009 | -3,054.36% | 541.07% |
2008 | -476.45% | -72.93% |
2007 | -1,760.34% | -7489.15% |
2006 | 23.82% | -100.66% |
2005 | -3,600.61% | -77.14% |
2004 | -15,749.47% | 70.61% |
2003 | -9,231.29% | 6764.93% |
2002 | -134.47% | -15.65% |
2001 | -159.43% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Novartis NVS | 17.27% | -279.15% | ๐จ๐ญ Switzerland |
Pfizer PFE | 34.61% | -459.02% | ๐บ๐ธ USA |
Cardinal Health CAH | -0.42% | -95.64% | ๐บ๐ธ USA |
Jazz Pharmaceuticals JAZZ | -6.99% | -27.49% | ๐ฎ๐ช Ireland |
Evoke Pharma
EVOK | -307.90% | 3,093.98% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | -1,520.92% | 15,677.18% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -20.53% | 112.97% | ๐ฎ๐ฑ Israel |
Royalty Pharma RPRX | 27.89% | -389.32% | ๐ฌ๐ง UK |
Lannett Company LCI | -43.36% | 349.79% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.